CEO

Mammography :: iCAD comments on recent article evaluating computer-aided detection and mammography

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, commented on an article published in the New England Journal of Medicine entitled, “Influence of Computer Aided Detection on Performance of Screening.” CAD uses sophisticated algorithms to identify areas of interest on a mammography film, acting as a “second set of eyes” for the radiologist.

MRI :: New technology offers hope of safe MRI exams

As the diagnostic capability of MRI continues to advance, and as the availability of MRI machines increases worldwide, so should the availability of implantable devices that are MRI safe. This advance is urgently needed says one executive.

Medicare :: Kinetic Concepts responds to Medicare Bidding Rule

Kinetic Concepts, Inc. (NYSE:KCI), a global medical technology company with leadership positions in advanced wound care and therapeutic surfaces, issued a statement on the recently-released final competitive bidding rule by the Centers for Medicare and Medicaid Services (“CMS”).

Sleep :: Cephalon’s Nuvigil approved for new drug application by FDA

Cephalon, Inc. (Nasdaq: CEPH) announced that it has received an approvable letter, together with draft labeling, from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for NUVIGIL(TM) (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift work sleep disorder (SWSD).

Asthma :: Theravance’s asthma drugs effective in clinical trials

Theravance, Inc. (NASDAQ: THRX) announced the results of two studies in an ongoing Phase 2b clinical program to assess the efficacy and safety of the investigational bronchodilators GSK642444 (‘444) and GSK159797 (‘797), the lead long-acting Beta2 agonist (LABA) compounds in the Beyond Advair collaboration with GlaxoSmithKline (GSK).

Sleep Apnea :: Cephalon’s Nuvigil approved for sleep apnea, sleep disorders

Cephalon, Inc. (Nasdaq: CEPH) announced that it has received an approvable letter, together with draft labeling, from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for NUVIGIL(TM) (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift work sleep disorder (SWSD).

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack